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Abstract
Prostate cancer is the second leading cause of cancer related death in American men. Development and progression of
clinically localized prostate cancer is highly dependent on androgen signaling. Metastatic tumors are initially responsive to
anti-androgen therapy, however become resistant to this regimen upon progression. Genomic and proteomic studies have
implicated a role for androgen in regulating metabolic processes in prostate cancer. However, there have been no
metabolomic profiling studies conducted thus far that have examined androgen-regulated biochemical processes in
prostate cancer. Here, we have used unbiased metabolomic profiling coupled with enrichment-based bioprocess mapping
to obtain insights into the biochemical alterations mediated by androgen in prostate cancer cell lines. Our findings indicate
that androgen exposure results in elevation of amino acid metabolism and alteration of methylation potential in prostate
cancer cells. Further, metabolic phenotyping studies confirm higher flux through pathways associated with amino acid
metabolism in prostate cancer cells treated with androgen. These findings provide insight into the potential biochemical
processes regulated by androgen signaling in prostate cancer. Clinically, if validated, these pathways could be exploited to
develop therapeutic strategies that supplement current androgen ablative treatments while the observed androgen-
regulated metabolic signatures could be employed as biomarkers that presage the development of castrate-resistant
prostate cancer.
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Introduction
Prostate cancer (PCa) is the commonest solid organ malignancy
diagnosed in men in the United States and is the second leading
cause of cancer related death in American men [1]. Androgen and
the androgen receptor (AR) play an important role in development
and progression of PCa, and androgen ablation is one of the main
therapeutic options for the treatment of locally advanced or
metastatic PCa [2]. Nearly 90% of all patients with metastatic
prostate cancer initially respond to castration-induced androgen
withdrawal; however, this treatment is often effective for less than
2 years and subsequently progresses to a castration resistant state
(castrate resistant prostate cancer, CRPC). CRPC is a lethal
disease. [3]. In spite of its clinical resistance to androgen
deprivation therapy, CRPC expresses AR [4] and exhibits active
androgen signaling through non-traditional activation of the
androgen receptor signaling axis [5]. This is best illustrated by
the observation of increasing levels of serum prostate specific
antigen (PSA), which is an androgen regulated protein and
currently used as a marker for biochemical recurrence of the
tumor, despite the development of CRPC [6]. It is still debated as
to whether this AR activity in CRPC is mediated by high affinity
receptors that are sensitive to low levels of circulating androgens
or, whether the receptor gains the ability to promiscuously interact
with other steroid hormones [4,7,8]. The latter is supported by
studies that have described a frequent mutation (T877A) within
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binding other steroid hormones and thereby overcoming a specific
requirement for androgens [9,10,11]. Importantly however, there
are no markers currently available, to predict if the tumor will
progress into a castrate resistant state. Thus, an understanding of
the molecular alterations that result from androgen action in
prostate cancer is essential. Multiple groups have interrogated
androgen-regulated changes at the transcriptome and proteome
levels in PCa cell lines, using gene expression arrays and mass
spectrometry [12,13,14,15,16,17,18]. One such seminal study
using affymetrix oligonucleotide arrays highlighted the association
of androgen signaling in PCa cells with metabolic processes
associated with stress responses [19]. Furthermore, androgen-
driven proliferation of PCa cells has been shown to involve
activation of mammalian target of rapamycin (m-TOR)
[20,21,22,23] that by itself is sensitive to metabolic perturbations
in the tumor [24,25]. In spite of this association, there is limited
insight into the biochemical alterations induced by androgen
action in PCa cells. Using integrative analysis of matched gene
expression and proteomic data, earlier we had predicted the
activation of amino acid metabolism in androgen-treated LNCaP
(androgen sensitive) prostate cancer cells [26]. This expectation
was further strengthened by metabolomic profiling of PCa tissues
that revealed amino acid metabolism as being one of the hallmarks
for early tumor development [27]. Here, we employ mass
spectrometry-based profiling of the metabolome of androgen-
treated PCa cells, nominate altered metabolites, identify and
validate biochemical pathways and evaluate the hormone
associated signature in patient-derived tissues. Our results are
indicative of androgen-induced elevation of amino acid metabo-
lism and alteration of methylation potential in PCa cells, both of
which corroborate our earlier findings using patient-derived
localized and metastatic PCa tissues [27].
Methods
Cell lines
Prostate cell lines (Immortalized benign – RWPE; androgen-
non-responsive – PC3, DU145 and androgen-responsive – VCaP,
and LNCaP) were purchased from American Type Culture
Collection (ATCC, Manassas, VA). RWPE cells were grown in
keratinocyte-SFM media (Invitrogen Corp., Carlsbad, CA)
supplemented with 5 ng/ml epidermal growth factor (EGF) and
50 mg/ml bovine pitutary extract (Invitrogen Corp., Carlsbad,
CA). VCaP cells were grown in DMEM-Glutamax media
(Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS; Hyclone Labs, Thermo Scientific, Rockford,
IL) and 1% penicillin-streptomycin (Hyclone Labs, Thermo
Scientific, Rockford, IL). DU145 cells were grown in Minimum
Essential Media (MEM) (Invitrogen Corp., Carlsbad, CA)
supplemented with 10% FBS (Hyclone Labs, Thermo Scientific,
Rockford, IL), 1% penicillin-streptomycin (Hyclone Labs, Thermo
Scientific, Rockford, IL) and 1% HEPES (Hyclone Labs, Thermo
Scientific, Rockford, IL). PC3 and LNCaP cells, were grown in
RPMI-1640 media (Invitrogen Corp., Carlsbad, CA) supplement-
ed with 10% fetal bovine serum (FBS; Hyclone Labs, Thermo
Scientific, Rockford, IL) and 1% penicillin-streptomycin (Hyclone
Labs, Thermo Scientific, Rockford, IL).. All cells were maintained
at 37uC and 5% CO2.
Androgen (R1881) treatment
Equal number of VCaP cells were plated and grown to 60%
confluency in DMEM-Glutamax medium as described above.
Medium was then replaced for two days by phenol-red free RPMI-
1640 medium supplemented with 10% charcoal-stripped FBS and
1% penicillin-streptomycin (Hyclone Labs, Thermo Scientific,
Rockford, IL). One set of cells were treated with 10 nM synthetic
androgen, methyltrienolone (R1881; Perkin Elmer, Waltham,
MA), for either 24 or 48 hrs, whereas vehicle-treated cells (treated
with ethanol) served as controls. At the end of the treatment, cells
were, trypsinized, pelleted, washed with 50 mM phosphate
buffered saline (PBS, pH 7.4) and stored at 2140uC until further
analyses.
Sample preparation for mass spectrometry-based
examination of metabolome in cell lines
Mass spectrometry-based metabolomics profiling was per-
formed on frozen prostate cell pellets (,10 million cells). The
process of metabolite extraction involved introduction of equimo-
lar mixture of 11 standard compounds dissolved in methanol
(Epibrassinolide, [D3] Testosterone, [
15N] Anthranilic acid,
Zeatine, Jasmonic acid, Gibberelic acid, [D4] Estrone, [
15N]-
Tryptophan, [D4] Thymine, [
13C] Creatinine and [
15N] Arginine)
followed by homogenization of the cells. The homogenate was
then subjected to extraction with sequential use of aqueous (chilled
water) and organic (chilled methanol and chloroform) solvents in
the following ratio 1:4:3:1 (water:methanol:chloroform:water)
[28]. The resulting extracts were de-proteinized using a 3 KDa
molecular filter (Amicon Ultracel -3K Membrane, Millipore
Corporation, Billerica, MA) and the filtrate containing metabolites
were dried under vacuum (Genevac EZ-2
plus, Gardiner, NY).
Prior to mass spectrometry analysis, the dried extract was
resuspended in identical volume of injection solvent composed of
water:methanol (50:50) with 0.2% acetic acid and subjected to
liquid chromatography (LC) mass spectrometry. As additional
controls to monitor the profiling process, an equimolar mixture of
11 standard compounds (Epibrassinolide, [D3] Testosterone, [
15N]
Anthranilic acid, Zeatine, Jasmonic acid, Gibberelic acid, [D4]
Estrone, (
15N) Tryptophan, [D4] Thymine, [
13C] Creatinine, and
[
15N] Arginine) and a characterized pool of mouse liver (extracted
in tandem with cell lines) were analyzed along with the cell line
samples. Each of these controls, were included multiple times into
the randomization scheme such that samples preparation and
analytical variability could be constantly monitored. Furthermore,
analysis of each cell line was succeeded by at least two blank runs,
to prevent any carryover of metabolites between samples. Figure
S1 illustrates the reproducibility in the profiling process monitored
using the standard mixture described above. Notably the CV for
the entire profiling process measured using five independent
replicates of the mouse liver extract mentioned above was less than
5%.
Liquid Chromatography/Mass Spectrometry (LC/MS)
The LC/MS portion of the unbiased profiling platform is based
on a 1200 SL Rapid resolution LC and a 6520 Quadrapole Time
Of Flight (Q-TOF) mass spectrometer (Agilent Technologies,
Santa Clara, CA). The samples were independently examined in
both positive and negative ionization modes using a dual
Electrospray Ionization (ESI) source. Real time mass correction
during mass spectrometry was achieved by infusion of a standard
mixture of reference ions using an independent 1200 SL Rapid
resolution LC isocratic pump equipped with 100:1 splitter to
output a flow rate of 5 ml/min. This reference mixture supplied by
the vendor contained ions with m/z 121.050873, 922.009798 and
119.03632, 966.000725 for mass correction in the positive (+) and
negative (2) ionization modes respectively. A mass range between
50–1000 m/z was employed for the entire unbiased profiling
process. The data acquisition during the analysis was controlled
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parameters used during the mass spectrometry included the
following: 1) source conditions: capillary voltage, 4000 V (negative
mode 3500 V), 2) source temperature was 325uC, 3) drying gas
was used at 10 l/min 4), nebulizer pressure was maintained at 45
psig (reference ion nebulizer 10 psig), 5) fragmentor voltage was set
at 140, and 6) skimmer voltage was maintained at 65 V. For the
entire analysis, ultra high pure nitrogen was used as the nebulizer
and collision gas. For collision induced dissociation (CID)
experiments, the precursor ion was selected using the quadrupole
analyzer set to high resolution mode while the product ions were
analyzed by the TOF analyzer. The collision energies in all the
experiments were set between 10–40 eV unless otherwise
specified. The spectra for the samples analyzed in this study were
recorded under identical experimental conditions. LC solvents
used for the entire study were purchased from Burdick & Jackson
(Muskegon, MI), and used without further purification.
The reverse phase (RP) chromatographic separation on the LC-
QTOF employed a gradient using Water (solvent A) and
Methanol (MeOH, solvent B) (both solvents were modified by
the addition of 0.2% Acetic acid). The binary pump flow rate was
0.6 ml/min with an initial solvent composition of 2% B. The
gradient was operated from 2% B to 98% B over a 13 minute
period, followed by 98% B for 6 min and 5 min post (sample
analysis) time. A column system consisting of a guard column
Zorbax SB-C8 (2.1630 mm, 3.5 um) and analytical column
Zorbax SB-Aq (Agilent Technologies, CA) (2.1650 mm,
1.8 um,) was used for the carrying out the reverse phase
separation. The column temperature was maintained at 60uC
throughout the chromatographic process. Further, all samples
were kept at 4uC prior to their mass spectrometry-based
metabolomic analysis. Mass spectral data was acquired in both
centroid and profile modes. To monitor any run to run variability,
the flow rates and pressure curves for each of the LC-associated
pumps were collected and stored.
The LC coupled Triple Quadrupole Mass Spectrometry (QQQ
Agilent Technologies, Santa Clara CA) was used for targeted
assessment of compounds using Single Reaction Monitoring
(SRM) strategy. The operational parameters for this mass
spectrometer included 1) source conditions capillary voltage of
3000 V and source temperature of 350uC, 2) drying gas
maintained at 10 l/min, 3) nebulizer pressure set at 35 psig and
4) fragmentor voltage set at 70 V. The collision energies used for
fragmentation was set at 10–40 eV unless otherwise stated.
The reverse phase (RP) chromatographic separation on the LC-
QQQ employed a gradient containing Water (solvent A) and
Acetonitrile (ACN, solvent B) (both solvents were modified by the
addition of 0.2% Acetic acid and 0.1% formic acid). Chromato-
graphic separation was performed on a Zorbax Eclipse XDB-C18
column (Agilent Technologies, CA) (5064.6 mm i.d.; 1.8 mm)
maintained at 37uC and a flow rate of 0.2 ml/min. The solvent at
the start of the gradient was 2% B which was then gradually
stepped up to 30% B over 6.5 minutes followed by an increase to
90% B over the next 0.5 minutes, 95% B for an additional
5 minutes and stepped down to 2% B for a period of 8 minutes.
This was followed by a post-sample equilibration for an additional
5 minutes. Notably, the column was washed and reconditioned
after every 50 injections.
The aqueous normal phase (ANP) chromatographic separation
on the LC-QQQ employed a gradient containing Acetonitirle
(ACN, solvent A): Water (solvent B) with both solvents modified by
the addition of 0.2% Acetic acid and 0.1% formic acid. The flow
rate was set at 0.4 ml/min. The initial solvent was 95%A with a
gradient from 95%A to 90%A over 3 minute period, 90%A–
80%A in 2 min, followed by 80%A–75%A in 1 min, 75%A–
55%A in 2 min, 55%A–40%A in 2 min, 40%A–30%A in 2 min,
30%A–20%A in 2 min, 20%A–95%A in 1 min and 95%A for
5 min. The column was then reconditioned back to starting
conditions. A Diamond Hydride column (MicroSolv Technology,
Eatontown, NJ) (4 um, 100A 2.16150 mm) was maintained in
temperature controlled chamber (37uC) and used for compound
separation. During the unbiased and targeted metabolomic
profiling process a few compounds are redundantly visualized
across multiple platforms. With the understanding that the
sensitivity and linearity are vastly different from interface to
interface, these redundancies are used as a part of the quality
control process. Furthermore, the rigorous quality control adopted
in this study involved a chromatographic separation that had less
than 0.1 minute variation in retention time of detected com-
pounds between experiments (Figure S1). Additionally we also
used internal standards containing equimolar mixture of pure
compounds as well as a characterized pool of liver specimen for
controlling process-associated variation. Both these controls were
repeatedly analyzed in tandem with the cell line samples. Also, to
ensure uniformity in the profiling process, all the columns and
solvents were purchased from a single manufacturer’s lot at the
start of these experiments.
In addition to the unbiased profiling described above,
evaluation of alanine and sarcosine was carried out using isotope
dilution gas chromatography-coupled mass spectrometry. Here
residual water was removed from the samples by forming an
azeotrope with 100 uL of dimethylformamide (DMF), and drying
the suspension under vacuum. All of the samples were injected
using an on column injector and an Agilent 6890N gas
chromatograph equipped with a 15-m DB-5 capillary column
(inner diameter, 0.2 mm; film thickness, 0.33 micron; J & W
Scientific Folsom, CA) interfaced with an Agilent 5975 MSD mass
detector. The t-butyl dimethylsilyl derivatives of sarcosine were
quantified by selected ion monitoring (SIM), using isotope dilution
electron-impact ionization GC/MS. The levels of alanine and
sarcosine that eluted at 3.8 and 4.07 minutes respectively, were
quantified using their respective ratio between the ion of m/z 232
derived from native metabolite ([M-O-t-butyl-dimethylsilyl]
2) and
the ions of m/z 233 and 235 respectively for alanine and sarcosine,
derived from the isotopically labeled deuteriated internal standard
[
2H3] for sarcosine. The limit of detection (signal/noise.10) was
,0.1 picomole for sarcosine using isotope dilution GC/MS.
Metabolomic Phenotyping Microarrays
The metabolic phenotyping was performed using 96-well plates
containing various metabolites as sole nutrient substrates. The
nutrient containing plates were obtained from Biolog Inc
(Hayward, CA) and the assay was performed as per the
manufacturer’s instruction. A total of 88 sugars, 5 nucleotides
and 29 amino acids were examined as substrates on two 96-well
plates, labeled M1 and M2 by the manufacturer. Essentially, the
assay measures the utilization of these metabolites by the growing
cells as function of NADH flux which is in turn measured by the
extent of reduction of tetrazolium dye. The latter is quantified by
spectrophotometry at 590 nm while any non-specific background
activity is assessed at 790 nm. For the metabolic phenotyping
studies, VCaP cells were starved for 96 h and seeded into the wells
of the 96-well plate at a density of 20,000 cells/well. Notably, the
VCaP cells were either treated with 10 nM R1881 or vehicle
(ethanol) at the time of seeding. The cells were then allowed to
grow for 24 h at 37 C at 5% CO2. Following 24 h incubation,
NADH flux was measured by monitoring the optical density at
590 nm using a spectrophotometer. Simultaneously, readings at
Metabolomic Profiling of Prostate Cancer Cells
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reading was taken at 24 h after androgen addition and subsequent
readings were taken at 1 h intervals up to 30
th hour, followed by
three additional readings at 34
th,4 2
nd and 48
th hrs post-androgen
addition. The data was tabulated in an excel sheet and analyzed as
described under Statistical Methods.
Metabolomic Libraries
Metlin library (Agilent, Santa Clara, CA) was used to search the
mass spectral data. The library was created using approximately
1000 commercially available compounds whose retention time was
defined using the RP and ANP chromatographic methods
described above. Additionally, the mass and fragment ion
information for each of these standard compounds were also
obtained in both positive and negative ionization modes and
included in the Metlin library.
Statistical Analysis
Metabolites with more than 60% missing values were removed
from the analysis. The metabolic data is left censored due to
thresholding of the mass spectrometer data. To account for
differences in missingness patterns across different classes,
distribution of proportion of missing values in androgen responsive
(ARD), androgen non-responsive (ARI) and benign (Ben) samples
were examined and compounds with more than 85% missing
values in each group and less than 60% missing values overall were
considered to have biological missingness. Androgen treated and
control samples were treated similarly. Missing metabolite
measurements for these metabolites were replaced (imputed) with
the detection level (2000). The missing measures in the remainder
of metabolites were imputed using the nearest neighbor algorithm
with k=5 using the R-package pamr. Imputed data were then
log2 transformed. Normalization for Q-TOF data was done using
quantile normalization per samples using the limma R-package.
QQQ samples were normalized by median centering and IQR
scaling.
Heatmaps, boxplots and Venn diagrams were drawn using R-
packages gplot, stats and limma, respectively. Data obtained from
different platforms were then scaled per compound and compared
across samples. The samples for duplicated compounds were
combined by averaging over samples resulted from multiple
occurrences of the same compounds. Hierarchical clustering was
performed using complete linkage with Pearson’s correlation. A
two-sided t-test was used to assess the association of each
metabolite with the androgen responsiveness status in a two-
sample test. The resulting p-values were then adjusted for multiple
testing using FDR with q*=0.2, by calculating the q-values using
the R-package fdrtool [29].
Data from metabolic phenotyping assays were first corrected for
background signal, obtained from readings of empty wells. The
data were then adjusted by subtracting average values of three
negative control wells from all other samples at each time point.
The effect of androgen treatment on prostate cancer cells grown in
amino acid and sugar plates in comparison to control cells were
compared using heatmaps and boxplots. In addition, gene set
analysis (R-package GSA [30]) was used to assess the overall
enrichment of amino acid and sugar pathways, in the respective
plates, at each time point.
Results
Metabolomic profiling of prostate-derived cell lines
In an effort to profile the androgen-regulated metabolome in
prostate cancer, we used liquid chromatography coupled with
mass spectrometry to interrogate the relative levels of metabolites
across prostate-derived cell lines (Immortalized benign – RWPE;
androgen-non-responsive – PC3 and DU145 and androgen-
responsive – VCaP, and LNCaP). In addition to delineating
prostate cancer-specific (PCa) metabolic profiles, we also examined
metabolic changes in androgen-responsive (ARD) vs non-respon-
sive cells (ARI), as well as those directly regulated by androgen in
VCaP cells. As outlined in Figure 1, the unbiased metabolomic
profiling platform used in this study consisted of both reverse
phase and aqueous normal phase chromatography coupled with 1)
electrospray ionization (ESI) in the positive ion mode (+) and 2)
ESI in the negative ion mode (2). In addition, a targeted
assessment of 57 compounds was performed using Single Reaction
Monitoring (SRM) on a triple quadrupole mass spectrometer
operated in (+) and (2) ion modes respectively (Figure 1). The cell
line-derived mass spectrometry profiles were subjected to pre-
processing that involved data filtering, imputation, logarithmic
transformation and normalization as illustrated in Figure 1. The
normalized data was then interrogated for metabolites that
distinguish 1) benign prostate cell line (Ben) from prostate cancer
cell lines (PCa) 2) androgen responsive prostate cancer cells (ARD)
from androgen independent cells (ARI) and 3) androgen-treated
prostate cancer cells from untreated controls. Further, the
metabolites that distinguished ARD and ARI cell lines were
evaluated in localized and metastatic tissues, using the tissue-
derived metabolomic profiles that were earlier published by our
group [27]. The class-specific metabolic signatures were subjected
to enrichment-based bioprocess mapping followed by validation
using in vitro metabolic phenotyping experiments.
A total of 1553 compounds were detected across the six prostate
cell lines using the different mass spectrometry methods used in
this study (see above, Figure 2A). Of these, 40 compounds were
detected only in Ben while 102 and 55 compounds respectively
were seen in ARI and ARD cell lines (Figure 2B). Notably, this
compendium contained 72 named metabolites (Figure 2C). A
hierarchical clustering profile based on compounds with significant
differential expression perfectly delineates the prostate cell lines
(Figure 2D).
Specific metabolic profiles distinguish Ben from PCa and
ARD from ARI
To delineate the metabolomic alterations between Ben and PCa
cell lines, we used a 2-sample t-test. A total of 674/1553
compounds were differential across these two classes after multiple
comparison adjustment at a false discovery rate (FDR) of 20%.
Included in this list were 29 named metabolites whose relative
levels are shown in Figure 3A. This altered metabolomic
signature in PCa cell lines contained elevated levels of amino
acids like sarcosine, threonine, phenylalanine and alanine as well
as higher levels of compounds associated with nitrogen metabolism
like creatine, creatinine, citrulline and N-acetyl spermine. On the
other hand, levels of metabolites belonging to tryptophan
metabolism namely tryptophan, 1-methyl tryptophan and kyneu-
ric acid were reduced in PCa compared to Ben. Similarly, 913/
1553 compounds were altered between ARI and ARD PCa cell
lines (Figure 3B). The altered list included 52 named metabolites
among which levels of spermine, N1-acetylspermine and amino
acids like serine, threonine, lysine, homocysteine, asparagine,
alanine, glutamic acid etc, were elevated in ARD (Figure 3B). On
the contrary, levels of S-adenosylmethione (SAM, methylation
currency of the cell) were reduced in ARD cells with a
concomitant increase in levels of its break down product,
homocysteine (Figure 3B). This is suggestive of increased
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21417Figure 1. Metabolomic profiling of prostate cell lines. Illustration of the various steps involved in metabolomic profiling of prostate cell lines.
The major steps involved metabolite extraction and separation, mass spectrometry-based detection, spectral analysis, data normalization, delineation
of class-specific metabolites and altered pathways and their functional characterization. The variation in sample extraction, separation and mass
spectrometry were controlled using spiked standards and assessed using various quality control parameters (Figure S1).
doi:10.1371/journal.pone.0021417.g001
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our earlier findings on advanced prostate cancer tissues [27].
Integrative Molecular Concept Modeling of PCa-derived
metabolome
Upon delineating the metabolomic patterns for Ben, ARD and
ARI prostate cell lines, we subsequently pursued evaluation of
these changes in the context of biochemical pathways and
delineation of altered biochemical processes during prostate
cancer development and progression keeping in context its
response to androgen. To delineate the overall biological processes
that are altered in prostate cancer cell lines, as well as in androgen-
responsive prostate cancer cells, the class-specific coordinated
expression profiles of metabolites described above were examined
using Oncomine Concept Maps (OCM, www.oncomine.org)
[31,32]. Here a ‘molecular concept’ is defined as any set of
molecular components that are related in some biologically
meaningful way. For this analysis, we used molecular concepts
of two general types: (1) gene and protein annotations from
external databases, and (2) computationally-derived regulatory
networks. The external annotation included chromosomal loca-
tions, protein domains and families, molecular functions, cellular
localizations, biological processes, signaling and metabolic path-
ways, protein-protein interaction networks, protein complexes,
and gene expression signatures. The regulatory networks were
derived by scanning human promoters for known transcription
factor motifs and by comparative genomics analyses that identified
conserved promoter and 39UTR elements. In total, data from 13
databases and 335 high-throughput datasets were collected and
analyzed. Prior to the enrichment analysis, significant metabolites
were assigned to their compound IDs using Kyoto Encyclopedia of
Genes and Genomes (KEGG, www.genome.jp/kegg). These were
again converted into their corresponding enzyme-gene IDs
(EGID) using KEGG, with the premise that metabolites are
functional end products of activity of their corresponding enzymes.
The resulting EGID’s obtained from the class-specific metabolome
were then used to select molecular concepts of potential interest
where enrichment analysis was carried out against a null set
containing a compendium of all EGIDs found in KEGG. The
molecular concepts that were selected for were significant at an
Figure 2. Metabolome of prostate cancer cell lines. A) Heat map representation of hierarchical clustering of 1,553 metabolites across 5
prostate cell lines. Sample classes are indicated by the colored bars [benign=green, androgen non-responsive PCa (ARI): yellow and androgen
responsive PCa (ARD): red bar]. Columns represent individual cell lines and rows refer to distinct metabolites. Shades of yellow represent elevationo f
a metabolite and shades of blue represent decrease of a metabolite relative to the median metabolite levels (see color scale). B) Venn diagram
representing the distribution of 1,553 metabolites measured across benign (RWPE), ARI (DU145 and PC3) and ARD (LNCaP and VCaP) cell lines using
liquid chromatography coupled mass spectrometry. C) same as in (A), but for 72 named compounds D) Dendrogram representing hierarchical
clustering of the prostate-related cell lines described in B, using compounds with significant differential expression.
doi:10.1371/journal.pone.0021417.g002
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21417Figure 3. Metabolic alterations in prostate cancer cell lines. A) Heat map showing 29 named differential metabolites in prostate cancer cells
relative to benign cell line (p,0.05, FDR=20%), derived using a t-test coupled with permutations (n=1,000) to determine the p-values for comparing
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systematically link metabolomic signatures to bioprocesses associ-
ated with prostate cancer and regulated by androgen action. A
subset of selected molecular concepts enriched by the PCa-specific
metabolome is displayed in Figure 3C and listed along with the
corresponding FDR adjusted q-values in supplementary Table
S1. Further, the list of all the concepts that were enriched by the
PCa-specific metabolome, are listed in supplementary Table S2.
Notably, the PCa-specific metabolic profiles enriched for
multiple interconnected concepts that described amino acid
metabolism, similar to those observed earlier upon integrative
analysis of androgen-regulated transcriptomic and proteomic
signatures [33] (Figure 3C, yellow bridges). These concepts
described enriched metabolic activity for proline, arginine,
alanine, aspartate, glutamate, glutamine and histidine as well as
transaminase activity and mobilization of the resulting nitrogen via
the urea cycle. A second set of concepts described utilization of
these amino acids for protein synthesis via enrichment of
aminoacyl-tRNA’s and translational machinery. Interestingly,
the metabolomic signature that delineated ARD from ARI also
enriched for similar concepts describing elevated amino acid
metabolism in androgen responsive cells (Figure S2). In addition,
the PCa-specific metabolic signature also enriched for nucleotidase
and ligase activity, suggestive of cell proliferation (Figure 3C).
Delineation of androgen-regulated metabolites in
hormone-responsive prostate cancer
Our results on prostate cancer cell lines, described above and
clinically localized tissues reported earlier [27], suggest a role for
androgen in preferentially elevating the ability of tumors to
metabolize amino acids. To confirm this and to delineate
additional metabolic niches affected by androgens, we carried
out an unbiased metabolic profiling of androgen-treated VCaP
cells. Specifically, these cells were treated with 10 nM R1881 for
24 or 48 h and their metabolome was examined against vehicle
(ethanol)-treated cells as controls, using methodology described in
Figure 1.
The metabolic compendia detected in 24 and 48 h androgen-
treated cells contained a total of 1024 and 1146 compounds
respectively, which completely distinguished androgen-treated
cells from controls in an unsupervised manner (Figure 4A).
Included in this time course compendia were 69 and 56 named
metabolites that were identified at the two time points respectively
(Figure 4B, C). Interestingly about 70% of the compounds
altered by androgen showed a consistent pattern of change at 24
and 48 h time points (Figure 4D). Furthermore, similar to the
results with PCa cell lines, the list of significant metabolites
elevated by androgen-treatment predominantly contained amino
acids and components of nitrogen metabolism pathway (Figure 4
B,C). Also, similar to our earlier findings with ARD cell lines,
androgen treatment of VCaP lowered the SAM levels in these cells
with a corresponding increase in levels of methylated metabolites
like N-methyl glycine (sarcosine), 2-methylglutaric acid, dimethyl-
glycine, methyl valine etc (Figure 4B). This suggests a possible
role for androgen in altering methylation potential of prostate
cancer cells which, as we reported earlier using tissues [27], is a
critical component for tumor progression.
To move beyond individual metabolic changes and understand
effect of androgens on the biochemical processes as a whole, we
performed the enrichment analysis of androgen-regulated meta-
bolic signature obtained 24 h after hormone treatment. A subset of
selected molecular concepts enriched by this signature, are
displayed in Figure 4D and, the list of all the concepts that were
enriched are listed in supplementary Table S3 along with their
corresponding FDR adjusted q-values.
Notably, as expected, the OCM analysis of androgen-regulated
metabolome revealed enrichment of amino acid metabolism
similar to our results with ARD cells, as well as portrayed multiple
concepts that reconfirmed androgen-mediated alteration of
methylation cascade (Figure 4D). Interestingly, while enrichment
of amino acid metabolism by androgen action echoed the
bioprocesses seen in clinically localized prostate cancer tissues,
the change in methylation potential was similar to findings seen in
metastatic tumors [27]. This suggests a potential dual role for
androgen, one wherein it enhances tumors ability to preferentially
utilize amino acids early on during their development, and a
second, where it potentiates change in the methylation potential
that is essential for tumor progression.
Metabolic phenotype analysis confirms androgen-
induced elevation of amino acid metabolism in prostate
cancer cells
The metabolomic profiling results described above highlight
androgen-induced dependence of prostate cancer cells on amino
acids for their development. To confirm this, we tested the ability
these cells to metabolize various nutrient substrates that included
sugars, nucleotides and amino acids. In essence, this so called
Metabolic Phenotyping Array (Biolog, Inc., Hayward, CA),
measured the flux of NADH generated as a result of utilization
of metabolic substrates by the actively proliferating cancer cells.
As shown in Figure 5A and plotted in Figure 5C, upon
androgen treatment, prostate cancer cells did not show any time-
dependent alteration in metabolism of sugar and nucleotide
substrates compared to untreated controls. However, starting at
24 h after androgen addition, these cells exhibit higher metabolism
of amino acids compared to untreated cells (Figures 5 B, C). This
elevated trend in amino acid metabolism in androgen-treated cells
was significant at 27 hrs post hormone treatment and persisted till
the 30 h time point (GSA p-values 0.0001 for all three time points,
See Statistical Methods for details) (Figures 5 B, C). This
increased activity in amino acid pathway correlates well with our
cell line-derived metabolic profiles that show androgen driven
elevation in levels of these metabolites in prostate cancer. Further,
this androgen-mediated increase in amino acid metabolism in
prostate cancer cells could potentially result in efficient utilization
of methionine (Figure 5B, methionine) that could in turn
generate higher levels of SAM, thus altering the methylation
potential of the cell.
Comparison of cell line-derived androgen-associated
metabolomic signature with tissue-derived metabolome
In this study, insights into the androgen-regulated signature was
obtained by first comparing the metabolome of hormone
independent cell lines (also termed ARI namely DU145 and
the groups. The heat map was generated after log scaling and quantile normalization of the data. The color scheme is the same as in Fig. 2A.
B) same as in (A) but for 52 named differential metabolites between ARI (yellow bar) and ARD (red bar) prostate cancer cells. C) Network view of the
molecular concept analysis for the metabolomic profiles of our ‘‘altered in PCa cell line signature’’ (grey node). Each node represents a molecular
concept or a set of biologically related genes. The node size is proportional to the number of genes in the concept. Each edge represents a
statistically significant enrichment (FDR q-value,0.2). Enriched concepts describing ‘‘amino acid metabolism’’ are indicated by yellow bridges.
doi:10.1371/journal.pone.0021417.g003
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termed ARD namely VCaP and LNCaP). Even though the
androgen response for these cell types have been well documented,
these cells exhibit differences in their molecular composition Thus
the metabolomic signature that distinguishes the ARD and ARI
cell lines could be confounded by differences in the molecular
make up of these cells in addition to the difference in their
response to androgen. To guard against the former we also
profiled the metabolome of VCaP cells treated with synthetic
androgen. A concordance analysis of the two metabolic signatures
(ARI vs ARD profile and metabolome altered by androgen
addition) was performed to home in on metabolites potentially
regulated by androgen. Further to determine their relevance in the
context of PCa development and progression, a similar meta-
analysis was carried out between the androgen responsive
metabolome and tissue-derived metabolomics signature, published
earlier [27]. The latter comprised of a compendia of metabolites
that were detected in organ-confined PCa (n=12) compared to
benign adjacent tissue (n=16) and in metastatic disease (n=14)
compared to localized PCa [27]. Thus in essence this meta-
analysis approach examined metabolomics fingerprints that
distinguish ARI vs ARD cells with metabolomics profiles of 1)
24 h androgen-treated cells 2) 48 h androgen-treated cells 3)
localized PCa and 4) metastatic disease.
A total of 43/52 metabolites present in at least one of the four
datasets described above, were selected for this meta-analysis
(Figure S3). Initially, we compared the metabolomic profiles that
distinguished ARI from ARD with those associated with
androgen-treated VCaP cells (24 and 48 h). In this comparison,
26/43 metabolites were concordant. Among others, the latter
included amino acids like asparagine, aspartic acid, glutamine,
glutamic acid, serine, threonine, histidine, alanine and tryptophan,
as well as components of nitrogen metabolism like creatine,
creatinine and acetylated-polyamine. Further this list also included
SAM and its metabolic product homocysteine.
Similarly, a total of 24/43 metabolites from the ARD vs ARI
signature showed a similar pattern of change in the metabolome
associated with organ-confined PCa and metastatic disease. The
compounds that were concordant in this comparison included
amino acids, SAM as well as components of tryptophan
breakdown like kynurenine, kynurenic acid and metabolites like
histamine, spermine and spermidine. Importantly, a total of 12
metabolites that distinguished PCa cell line based on their
response to androgen had similar pattern of expression in both
androgen-treated VCaP cells and patient-derived tissues. These
included SAM, nicotinamide adenine dinucleotide (NAD), aspar-
agine, serine, histidine, tryptophan, homocysteine, creatinine,
hypoxanthine, aspartic acid, tyrosine and lysine. OCM-based
enrichment analysis (using all the named metabolites detected in
ARD and ARI cell lines (n=72), as the null set) of this 12
metabolite signature revealed multiple concepts that portray
methionine metabolism, SAM activity and methylation
(FDR,20%, Figure S4, refer to Table S4 for a list of all
concepts enriched by the 12-metabolite signature with associated
p-values and q-values). Notably, these enriched concepts are
similar to the ones seen in metastatic PCa [27] and support our
notion that androgen action in PCa could alter methylation
potential and thus aid in progression of the tumor. Further study is
warranted to verify the role of these 12 metabolites in PCa.
Discussion
To delineate the biochemical processes altered by androgen
action, we adopted a strategy of global mass spectrometry-based
unbiased profiling of metabolome in prostate cancer cell lines. The
profiling data was then used to delineate altered bioprocesses using
bioinformatics-based pathway mapping followed by pathway
functional validation using metabolic phenotyping microarray
assays. Overall, we profiled both benign and prostate cancer cell
lines with the latter including both androgen responsive and non-
responsive cells. Although multiple groups have interrogated
androgen-regulated changes at the transcriptome and proteome
levels in these cell lines [12,13,14,15,16,17,18], the androgen-
induced metabolomic alterations in these cells have not been
reported. The need to define this stems from our earlier findings
on metabolomic profiles of prostate cancer tissues that revealed
alterations in amino acid metabolism and methylation potential as
hallmarks for indolent and advanced tumors respectively [27].
However, from that study it was not clear if these alterations were
influenced by androgens, a critical regulator for prostate cancer
development and progression.
The unbiased metabolomic assessments made in this study
employ highly reproducible chemo-centric chromatographic
separations of metabolites coupled to their detection using Q-
TOF/QQQ mass spectrometers. The overall process variation in
the profiling process was below 5% as monitored using multiple
sets of standards and characterized tissue extracts. Using such a
robust strategy, the study detected over 1000 compounds in
prostate-derived cell lines both in presence and absence of
androgen treatment. Importantly, these metabolic profiles could
delineate the cell lines into different classes in an unsupervised
hierarchical clustering, suggestive of existence of class-specific
metabolic niches. Accordingly, comparison of metabolic profiles
between PCa and Ben cell lines revealed altered levels of multiple
amino acids. Included in this list was sarcosine that was elevated in
PCa compared to benign, a finding that was concordant with our
earlier profiling study on prostate tissues [27]. Furthermore,
components of nitrogen metabolism, namely creatinine, citrulline,
creatinine and N1-acetyl spermine were also elevated, indicative of
increased amino acid utilization. Notably, this amino acid
addiction was reflected in the bioprocess enrichment wherein
most of the concepts enriched by the PCa-specific metabolome
highlighted altered amino acid metabolism. Further, this pro-
nounced alteration of amino acid metabolism was also observed in
androgen responsive prostate cancer cells compared to their
hormone non-responsive counterparts. The latter motivated us to
examine the role of androgen in instilling amino acid dependency
in prostate cancer cells. As expected, both the metabolic data and
bioprocess enrichment analysis confirmed elevation of amino acid
metabolic processes in prostate cancer. In addition, these also
are altered in VCaP prostate cancer cells 24 h after treatment with 10 nM synthetic androgen (R1881) compared to untreated controls, (p,0.05,
FDR=20%), derived using a t-test coupled with permutations (n=1,000) to determine the p-values for comparing the groups. The heat map was
generated after log scaling and quantile normalization of the data. The color scheme is the same as in Fig. 2A. C) same as in (B) but for metabolic
alterations after 48 h of androgen-treatment D) Correlation plot for metabolites altered at 24 h and 48 h post-androgen treatment in VCaP prostate
cancer cells E) Network view of the molecular concept analysis for the metabolomic profiles of our ‘‘Androgen-induced metabolomic signature’’ (grey
node). Each node represents a molecular concept or a set of biologically related genes. The node size is proportional to the number of genes in the
concept. Each edge represents a statistically significant enrichment (FDR q-value,0.2). Enriched concepts describing ‘‘amino acid metabolism’’ and
‘‘methylation potential’’ are indicated by yellow and red bridges respectively.
doi:10.1371/journal.pone.0021417.g004
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prostate cancer cells. This result was intriguing in the context of
our earlier findings with the metabolome of metastatic prostate
cancer that echoed elevated methylation potential [27]. Further-
more, methylation-induced epigenetic changes are known to be
causal in cancer progression [34,35,36,37,38,39,40]. Also, andro-
gen receptor expression in prostate cancer has long been known to
be regulated, in part, by methylation [41,42,43,44,45]. In light of
these studies, our results indicative of a role for androgen in
stimulating methylation potential is interesting. This, we believe,
could be a consequence of increased amino acid utilization by
prostate cancer cells, potentially under the influence of androgen.
We confirmed this using metabolic phenotyping microarrays that
revealed a time-dependent increase in utilization of amino acids by
prostate cancer cells upon androgen treatment without any
appreciable change in the steady state activity of sugar and
nucleotide metabolic pathways. This increase in amino acid
metabolism encompasses efficient utilization of methionine that
can generate higher levels of SAM, the methylation currency of
the cell. Interestingly, OCM analysis of the metabolic signature
that was concordant between cell lines and prostate cancer tissues
described the enrichment of methionine metabolism and SAM
activity, supporting the above premise. Furthermore, higher levels
of SAM could promote methylation as evidenced by elevated
levels of methylated metabolites like N-methylglycine, a.k.a.
sarcosine, 2-methyl glutaric acid, dimethylglycine, methyl alanine
etc in prostate cancer cells upon androgen treatment, as well as
increased expression of methyltransferases like EZH2, in meta-
static disease. From the clinical perspective, this finding of a role
for androgen in elevating cancer cell methylation potential could
have implications for the development of therapeutic agents [46].
This premise is supported by in vitro studies using 5-Aza-29-
deoxycytidine that have shown a decrease in prostate cacner cell
clonogenicity [47].
In summary, here we describe the androgen regulated
metabolome in prostate cancer cell lines (metabolomic alterations
induced by androgen) and compare these with prostate-derived
tissues that included benign, localized tumors and metastatic
disease. Our results indicate a potential role for androgen in
regulating prostate cancer cell amino acid metabolism as well as
methylation potential.
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